|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Adami HO, Signorello LB and Trichopoulos
D: Towards an understanding of breast cancer etiology. Semin Cancer
Biol. 8:255–262. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dumitrescu R and Cotarla I: Understanding
breast cancer risk - where do we stand in 2005? J Cell Mol Med.
9:208–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gessler M, Poustka A, Cavenee W, Neve RL,
Orkin SH and Bruns GA: Homozygous deletion in Wilms tumours of a
zinc-finger gene identified by chromosome jumping. Nature.
343:774–778. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haber DA, Park S, Maheswaran S, et al:
WT1-mediated growth suppression of Wilms tumor cells expressing a
WT1 splicing variant. Science. 262:2057–2059. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loeb DM, Evron E, Patel CB, et al: Wilms’
tumor suppressor gene (WT1) is expressed in primary breast
tumor despite tumor-specific promoter methylation. Cancer Res.
61:921–925. 2001.
|
|
7
|
Navakanit R, Graidist P, Leeanansaksiri W
and Dechsukum C: Growth inhibition of breast cancer cell line MCF-7
by siRNA silencing of Wilm tumor 1 gene. J Med Assoc Thai.
90:2416–2421. 2007.PubMed/NCBI
|
|
8
|
Miyoshi Y, Ando A, Egawa C, et al: High
expression of Wilms’ tumor suppressor gene predicts poor prognosis
in breast cancer patients. Clin Cancer Res. 8:1167–1171. 2002.
|
|
9
|
Oji Y, Miyoshi Y, Kiyotoh E, et al:
Absence of mutations in the Wilms’ tumor gene WT1 in primary
breast cancer. Jpn J Clin Oncol. 34:74–77. 2004.
|
|
10
|
Yang L, Han Y, Saurez Saiz F and Minden M:
A tumor suppressor and oncogene: the WT1 story. Leukemia.
21:868–876. 2007.PubMed/NCBI
|
|
11
|
Graidist P: The role of WT1 in breast and
other cancers: oncogene or tumor suppressor gene? Songkla Med J.
27:435–449. 2009.
|
|
12
|
Subik K, Lee JF, Baxter L, et al: The
expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by
immunohistochemical analysis in breast cancer cell lines. Breast
Cancer. 4:35–41. 2010.PubMed/NCBI
|
|
13
|
Filmus J, Pollak MN, Cailleau R and Buick
RN: MDA-468, a human breast cancer cell line with a high number of
epidermal growth factor (EGF) receptors, has an amplified EGF
receptor gene and is growth inhibited by EGF. Biochem Biophys Res
Commun. 128:898–905. 1985. View Article : Google Scholar
|
|
14
|
Armstrong DK, Kaufmann SH, Ottaviano YL,
Furuya Y, Buckley JA, Isaacs JT and Davidson NE: Epidermal growth
factor-mediated apoptosis of MDA-MB-468 human breast cancer cells.
Cancer Res. 54:5280–5283. 1994.PubMed/NCBI
|
|
15
|
Holiday LD and Speirs V: Choosing the
right cell line for breast cancer research. Breast Cancer Res.
13:2152011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guittaut M, Charpentier S, Normand M,
Dubois J, Raimond J and Legrand A: Identification of an internal
gene to the human Galectin-3 gene with two different overlapping
reading frames that do not encode Galectin-3. J Biol Chem.
276:2652–2657. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duneau M, Boyer-Guittaut P, Gonzalez P, et
al: Galig, a novel cell death gene that encodes a
mitochondrial protein promoting cytochrome c release. Exp
Cell Res. 302:194–205. 2005. View Article : Google Scholar
|
|
18
|
Robinet O, Mollet L, Gonzalez P, Normand
T, Charpentier S, Brulé F, et al: The mitogaligin protein is
addressed to the nucleus via a non-classical localization signal.
Biochem Biophys Res Commun. 392:53–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu K, Toral-Barza L, Discafani C, Zhang
WG, Skotnicki J, Frost P and Gibbons JJ: mTOR, a novel target in
breast cancer: the effect of CCI-779, an mTOR inhibitor, in
preclinical models of breast cancer. Endocr Relat Cancer.
8:249–258. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou H and Huang S: mTOR signaling in
cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene
Expr. 20:1–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Razmara M, Heldin CH and Lennartsson J:
Platelet-derived growth factor-induced Akt phosphorylation requires
mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphorylation
depends on mTOR/Raptor and phospholipase D. Cell Commun Signal.
11:32013.PubMed/NCBI
|
|
22
|
Bruening W, Moffett P, Chia S, Heinrich G
and Pelletier J: Identification of nuclear localization signals
within the zinc fingers of the WT1 tumor suppressor gene product.
FEBS Lett. 393:41–47. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Silberstein GB, Van Horn K, Strickland P,
Roberts CT Jr and Daniel CW: Altered expression of WT1 Wilms tumor
suppressor gene in human breast cancer. Proc Natl Acad Sci USA.
94:8132–8137. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Niksic M, Slight J, Sanford JR, Caceres FJ
and Hastie ND: The Wilms’ tumor protein (WT1) shuttles between
nucleus and cytoplasm and is present in functional polysomes. Hum
Mol Genet. 13:464–471. 2004.
|
|
25
|
Alberts B, Johnson A, Lewis J, Raff M,
Roberts K and Walter P: Molecular Biology of the Cell. 5th edition.
Garland Science; New York: 2008
|
|
26
|
Shang X, Marchioni F, Evelyn CR, et al:
Small-molecule inhibitors targeting G-protein-coupled Rho guanine
nucleotide exchange factors. Proc Natl Acad Sci USA. 110:3155–3160.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Janda E, Palmieri C, Pisano A, Pontoriero
M, Laccino E, Falcone C, et al: Btk regulation in human and mouse B
cells via protein kinase C phosphorylation of IBtkγ. Blood.
117:6520–6531. 2011.PubMed/NCBI
|
